XML 128 R71.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Liabilities related to business combinations and to non-controlling interests (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Business Combination [Abstract] |
Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests | Movements in liabilities related to business combinations and to non-controlling interests are shown below:
(€ million) | Bayer contingent consideration arising from the acquisition of Genzyme | MSD contingent consideration (European Vaccines business) | Shire contingent consideration arising from the acquisition of Translate Bio | Contingent consideration arising from acquisition of Amunix | Other | Total(a)
Balance at January 1, 2022 | 59 | 269 | 354 | — | 32 | 714
New transactions | — | — | — | 156 | — | 156
Payments made | (29) | (79) | — | — | (28) | (136)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)(b) | (9) | 14 | 2 | (2) | — | 5
Other movements | — | — | — | — | — | —
Currency translation differences | 5 | — | 24 | 11 | — | 40
Balance at December 31, 2022 | 26 | 204 | 380 | 165 | 4 | 779
New transactions | — | — | — | — | — | —
Payments made | (21) | (77) | — | (69) | — | (167)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)(b) | (5) | — | 74 | 45 | — | 114
Other movements | — | — | — | — | — | —
Currency translation differences | — | — | (13) | (4) | — | (17)
Balance at December 31, 2023 | — | 127 | 441 | 137 | 4 | 709
New transactions | — | — | — | — | — | —
Payments made | — | (70) | — | — | (1) | (71)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount)(b) | — | 16 | 94 | — | 1 | 109
Other movements | — | — | — | (137) | (3) | (139)
Currency translation differences | — | (1) | 33 | — | — | 33
Balance at December 31, 2024 | — | 72 | 568 | — | 1 | 641
(a)Portion due after more than one year: €569 million as of December 31, 2024 (€501 million as of December 31, 2023 and €674 million as of December 31, 2022); portion due within less than one year: €72 million as of December 31, 2024 (€208 million as of December 31, 2023 and €105 million as of December 31, 2022). (b)Amounts reported within the income statement line item Fair value remeasurement of contingent consideration, and mainly comprising unrealized gains and losses.
Summary of Maximum Amount of Contingent Consideration Payable and Firm Commitments to Buy Out Non-Controlling Interests | T he table below sets forth the maximum amount of contingent consideration payable in respect of already-marketed products:
December 31, 2024 |  | Payments due by period
(€ million) | Total | Less than 1 year | From 1 to 3 years | From 3 to 5 years | More than 5 years
Commitments relating to contingent consideration in connection with business combinations | 72 | 72 | — | — | —

X
- Definition Business Combination [Abstract] + References No definition available. + Details
Name: | sny_BusinessCombinationAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of changes in liabilities related to business combinations and to non-controlling interests. + References No definition available. + Details
Name: | sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNonControllingInterestsTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of maximum amount of contingent consideration payable and firm commitments to buy out non-controlling interests explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfMaximumAmountOfContingentConsiderationPayableAndFirmCommitmentsToBuyOutNonControllingInterestsExplanatoryTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration